UNSPSC 51162714: Guaiacol acetate

This classification denotes a topical anti-infective agent and expectorant with the molecular formula C9H10O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K5YN7743HC, chemically known as phenol, 2-methoxy-, 1-acetate, but more generally known as guaiacol acetate, which bears US NIH Compound Identifier 61155. European Medicines Agency schedules guaiacol acetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14027MIG.

Most nations, for tariff purposes, schedule guaiacol acetate under HS 29095000. SMILES: CC(=O)OC1CCCCC1OC.

UNSPSC 51162714 Guaiacol acetate is a Commodity code that in recent state and local procurement shows little activity aligned with its nominal chemical scope. The two recent opportunities tagged under this code involve naloxone and safe drug deactivation systems (Seminole County, Florida) and generic multi-source pharmaceuticals and OTC products (Minnesota Multistate Cooperative Purchasing Alliance), neither of which involves guaiacol acetate or its typical industrial and pharmaceutical chemical uses. The code mismatch suggests either data classification drift in the underlying procurement systems or that issuers are applying the code to broader pharmaceutical and health-supply categories beyond its intended scope.

The issuing bodies include a county health department (Seminole County) and a multi-state cooperative purchasing vehicle (MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement). Activity is concentrated in Florida and Minnesota, with MMCAP's reach extending to participating states including Oregon. Seminole County's IFB 60459723LAS sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries due by July 26, 2023 (note: the due date appears inconsistent with the June 30, 2026 posting date in the source record); MMCAP's RFP S1070000015802 solicited generic pharmaceuticals and OTC products from manufacturers with proposals due March 26, 2026. Neither solicitation is materially relevant to actual guaiacol acetate procurement activity. The code shows insufficient recent opportunity volume to support targeted pursuit.